Canurta Therapeutics

𝗖𝗮𝗻𝘂𝗿𝘁𝗮 𝗜𝗻𝗰. 𝗨𝗻𝘃𝗲𝗶𝗹𝘀 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗥𝗲𝗼𝗿𝗴𝗮𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻 & 𝗥𝗲𝗯𝗿𝗮𝗻𝗱𝗶𝗻𝗴: 𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝗖𝗮𝗻𝘂𝗿𝘁𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝘂𝗿𝘁𝗮 𝗡𝗮𝘁𝘂𝗿𝗮𝗹𝘀 We are pleased to announce a significant transformation in our corporate structure and brand architecture. The organization will now have two distinct operating arms: Canurta Inc, which will continue to do business as Canurta Therapeutics; and newly created Canurta Naturals. This structure aligns our brand identity more closely with each company’s mission and operational focus. 𝗖𝗮𝗻𝘂𝗿𝘁𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀: 𝗣𝗶𝗼𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗕𝗼𝘁𝗮𝗻𝗶𝗰𝗮𝗹 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 Canurta Inc. will be doing business as Canurta Therapeutics, reflecting its dedication to creating best-in-class botanical drugs. With a core focus on addressing inflammation and neurological disorders, Canurta Therapeutics represents the company's commitment to technology-driven drug development to address unmet needs for patients in new and optimized ways. 𝗖𝗮𝗻𝘂𝗿𝘁𝗮 𝗡𝗮𝘁𝘂𝗿𝗮𝗹𝘀: 𝗦𝗰𝗶𝗲𝗻𝗰𝗲-𝗟𝗲𝗱 𝗪𝗲𝗹𝗹𝗻𝗲𝘀𝘀 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝘀 The newly incorporated US sister company, Canurta Naturals, marks Canurta's strategic entry into the natural supplement market. Focused on the distribution and sale of potent, high-quality natural ingredients and supplements, Canurta Naturals aims to make a significant impact in the largest supplement market globally, the USA. 𝗨𝗻𝗶𝗳𝗶𝗲𝗱 𝗬𝗲𝘁 𝗗𝗶𝘀𝘁𝗶𝗻𝗰𝘁 "This rebranding marks a pivotal moment in our journey. As Canurta Therapeutics and Canurta Naturals, we stand better positioned to articulate our unique strengths and drive forward our mission of using botanical innovation to heal and transform at all life stages. Today’s health consumers expect quality and innovation across preventative wellness products and pharmaceuticals. We are excited to build trust and loyalty throughout their health journeys,” expressed Akeem Gardner, Founder and CEO of Canurta, on this new chapter. Canurta would like to recognize and thank its consultants and advisors on structure implementation and execution, with work completed by MNP and the MNP Future Leaders Program alongside Beganyi Professional Corporation, Goodlawyer and Doola. 𝗖𝗮𝗻𝘂𝗿𝘁𝗮 𝗡𝗮𝘁𝘂𝗿𝗮𝗹𝘀 𝘁𝗼 𝗟𝗮𝘂𝗻𝗰𝗵 𝗙𝗶𝗿𝘀𝘁 𝗡𝗮𝘁𝘂𝗿𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗕𝗿𝗮𝗻𝗱 𝗶𝗻 𝟮𝟬𝟮𝟰 We look forward to sharing more about our product launch later this year. Read the full article and subscribe to our newsletter to receive the latest updates on our new natural health brand: https://lnkd.in/gwhWVpNq

Delve into the extensive polyphenol expertise of Eric Soubeyrand, Research Associate at Canurta, and his contributions to our cutting-edge research. #canurtatherapeutics #innovation #drugdevelopment #pharmaInnovation #brainhealth #biotechnology #naturalcompounds #polyphenols

Eric Soubeyrand, Research Associate at Canurta, shares insights into his crucial role in purifying and synthesizing molecules, with a special focus on the biosynthesis of cannflavins. #canurtatherapeutics #innovation #drugdevelopment #pharmaInnovation #brainhealth #biotechnology #naturalcompounds #polyphenols

Kelly Boddington discusses her background in protein biochemistry and its relevance to her current work at Canurta. #canurtatherapeutics #innovation #drugdevelopment #pharmaInnovation #brainhealth #biotechnology #naturalcompounds #polyphenols

Kelly Boddington, Research Associate at Canurta, shares her transition from academic research to impactful therapeutic development. #innovation #biotechnology #polyphenols

Tariq Akhtar discusses the short- and long-term goals he has in mind for the ongoing research he’s conducting. #innovation #research #polyphenols

Tariq Akhtar discusses the benefits of dual-inhibition for treating chronic pain and inflammation, and how Canurta's molecules are proving to be a necessary alternative to mainstream options. #innovation #biotechnology #polyphenols

Inflammation and its role in chronic diseases are on the rise. Tariq Akhtar explains how understanding the mechanisms of hemp extracts can provide precise solutions to reduce pain and inflammation. #innovation #pharmaInnovation #polyphenols

Reflecting on the pharmaceutical landscape of 2023, natural products have played a significant role in drug development, with 10 new products introduced to the market. This year saw a notable shift from COVID-19 to an increase in new drug approvals, totaling 55 by the FDA, reminiscent of the impactful year of 2018. The rise of biologics and monoclonal antibodies (mAbs), with 12 approvals, highlights ongoing innovation. Read More Here: https://lnkd.in/gynX7zkj #innovation #drugdevelopment #polyphenols

Highlighting the importance of precise supply chain tracking, Cameron Parry discusses how blockchain technology ensures greater transparency and quality from biomass to final product. #canurtatherapeutics #innovation #pharmaInnovation #biotechnology #naturalcompounds #polyphenols